Gracell Biotechnologies, Inc. (GRCL)
| Market Cap | 847.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.99M |
| Shares Out | 65.56M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $12.93 |
| Previous Close | $12.69 |
| Change ($) | 0.24 |
| Change (%) | 1.89% |
| Day's Open | 12.91 |
| Day's Range | 12.52 - 13.39 |
| Day's Volume | 22,039 |
| 52-Week Range | 12.02 - 33.70 |
SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...
SUZHOU, China and SHANGHAI, China, April 05, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering ...
SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and ...
SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effic...
SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and dev...
Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled ...
SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effica...
SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and aff...
SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly effica...
China's Gracell Biotechnologies Lists on Nasdaq
Jan.10 -- William Cao, founder and chief executive officer of Gracell Biotechnologies, discusses the Shanghai-based company's initial public offering in the U.S. and its growth strategy. Gracell is deve...
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...
SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing...
Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, announced terms for its US IPO on Monday. The Suzhou, China-based company plans to raise $150 million by of...
Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Gracell Biotechnologies, Inc. has filed to go public with an IPO on the NASDAQ.
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and...
About GRCL
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms—FasTCAR and TruUCAR. Chimeric antigen receptor T cells, or CAR-T cells, can be classified as either autologous or allogeneic. Autologous CAR-T cells are derived from the T cells of the cancer patien... [Read more...]
| Industry Biotechnology | IPO Date Jan 8, 2021 |
| CEO William Wei Cao, Ph.D. B.M. | Employees 160 |
| Stock Exchange NASDAQ | Ticker Symbol GRCL |